What We're Reading: Page 398
Industry reads hand-picked by our editors
Jan 27, 2015
-
Medscape
EMA suspending almost 50 drugs over flawed CRO clinical studies
-
Sanofi tops new index that measures pharma's commitment to infectious diseases
-
-
Sanofi/Regeneron off to the races with priority review of cholesterol game-changer
-
Shire pleased as NPS Pharma wins Natpara approval
-
GSK denies reports of imminent job cuts in China
-
-
-
-
-
Jan 26, 2015
-
-
-
UPDATED: Sen. Elizabeth Warren proposes big new pharma fines to fund NIH research
-
Hindsight: Valeant CEO admits mistakes in approach to Allergan bid
-
-
-
-
Regulators get creative on Ebola vaccine testing as infections decline
-
Express Scripts determined to influence prices for cancer drugs
-
Jan 23, 2015
-
-
J&J: Regulatory delays in China are stymying drug approvals
-
-
Out with the old: Merck discontinues US sales of hep C med Victrelis
-
-
Salix Pharma reportedly exploring options, considering sale
-
REPORT: Takeda COO Weber approached for vacant Sanofi CEO post
-
UN Ebola chief requests one last $1 billion in funding to fight outbreak
-
Plaintiffs wanted: Law firms seek shareholders to launch a Sanofi kickback suit
-
Chasing transparency in the pharmaceutical industry: How much is enough?
Jan 22, 2015
-
Obama proposes genetic 'Precision Medicine Initiative' at State of the Union
-
4 key industry trends that will impact biopharma in 2015
-
India issues draft bioequivalence request format for drugs aimed for export
-
UPDATE: Pfizer gives poor nations modest discount after vax price blowback
-
-
J&J's Q4 earnings: A solid 2014
-
-
-
Ambitious RNA biotech Alnylam raising $450M, looking for acquisitions
-
Jan 21, 2015
-
One more push: Senators reintroduce bill to expedite antibiotic approval
-
China FDA to reverse course, allow online Rx drug sales
-
-
Hospira closes North Carolina plant over cost concerns
-
-
AbbVie strikes hep C discount deal with US state-based AIDS programs
-
UPDATED: Yet another major insurance company strikes hep C deal with Gilead
-
-
-
Jan 20, 2015
-
-
Blast from the past: Roche's dalcetrapib, HDL-raising meds could work for some patients
-
Pfizer warns UK MDs: Lyrica is still on patent for pain
-
Flu vaccine only 23% effective this season
-
-
J&J: Women were inappropriately pressured to file pelvic mesh suits
-
-
Pharma stocks plunge as Switzerland discontinues fixed-price peg to euro
-
-
Jan 16, 2015
-
-
AbbVie's Humira/hep C plans, bluebird bio, NIH funding, and even more from JPM15
-
-
Intrexon, Ziopharma invest $100M in MD Anderson cancer immunotherapy tech
-
-
-
Johnson & Johnson to release trial data
-
New Brilinta data supports extending use beyond one year
-
-
FDA approves novel weight-loss device
Previous
